Literature DB >> 9132826

Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma.

E J Sawyer1, A R Timothy.   

Abstract

The clinical picture of disseminated (stage 3 and 4) low grade non-Hodgkin's lymphoma (NHL) is one of continuing relapse. Management options include observation only in asymptomatic patients, single agent chlorambucil or localised radiotherapy in patients with symptomatic nodal disease. Radiation doses of 25-40 Gray in 10-20 fractions have been the standard approach in low grade NHL, but in 1994 Ganem et al. [Hematol. Oncol. 8: 225-233, 1994] reported the use of low dose radiotherapy (LDRT)--4 Gray in 2 fractions over 3 days--for the palliation of symptomatic disease in patients with disseminated, chemoresistant low grade NHL. We describe here our early experience with this schedule.

Entities:  

Mesh：

Year:  1997        PMID： 9132826     DOI： 10.1016/s0167-8140(96)01854-3

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  9 in total

Review 1.  Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.

Authors:  Frank Heinzelmann; Hellmut Ottinger; Marianne Engelhard; Martin Soekler; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

2.  Low dose palliative radiotherapy for refractory aggressive lymphoma.

Authors:  Osamu Tanaka; Masahiko Oguchi; Takayoshi Iida; Senji Kasahara; Hideko Goto; Takeshi Takahashi
Journal:  Rep Pract Oncol Radiother       Date:  2016-08-24

Review 3.  Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?

Authors:  Lena Specht
Journal:  Curr Treat Options Oncol       Date:  2016-01

4.  Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma.

Authors:  Carolina E Fasola; Jennifer C Jones; Derek D Huang; Quynh-Thu Le; Richard T Hoppe; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-29       Impact factor: 7.038

5.  Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.

Authors:  S K Luthy; A K Ng; B Silver; K O Degnan; D C Fisher; A S Freedman; P M Mauch
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

Review 6.  Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma.

Authors:  Daniel Rolf; Gabriele Reinartz; Stephan Rehn; Christopher Kittel; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

7.  Prospective Study of 4 Gy Radiotherapy for Orbital Mucosa-Associated Lymphoid Tissue Lymphoma (FORMAL).

Authors:  Jaehyeon Park; Ji Woon Yea; Se An Oh; Min Kyoung Kim; Jun Hyuk Son; Jae Won Park
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

8.  Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.

Authors:  Khalil Saleh; Jean-Marie Michot; Antoine Schernberg; Julien Lazarovici; Claude Chahine; Alina Danu; Nadine Khalife-Saleh; Julien Rossignol; David Ghez; Valentine Martin; Renaud Mazeron; Christophe Fermé; Angela Boros; Vincent Ribrag; Theodore Girinsky
Journal:  Cancer Med       Date:  2020-04-06       Impact factor: 4.452

9.  Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?

Authors:  Brandon S Imber; Karen W Chau; Jasme Lee; Jisun Lee; Dana L Casey; Joanna C Yang; N Ari Wijentunga; Annemarie Shepherd; Carla Hajj; Shunan Qi; Monica R Chelius; Paul A Hamlin; M Lia Palomba; Erel Joffe; Zhigang Zhang; Andrew D Zelenetz; Gilles A Salles; Joachim Yahalom
Journal:  Blood Adv       Date:  2021-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.